Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Vyndaqel
| Field | Information |
|---|---|
| Medication Name | Vyndaqel |
| Generic Name | Tafamidis |
| Purpose | Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. |
| Mechanism of Action | Stabilizes transthyretin (TTR), preventing it from misfolding and forming amyloid fibrils that deposit in the heart. |
| Dosage Forms | Oral capsules |
| Available Strengths | 20 mg |
| Dosage Frequency | 80 mg (four 20 mg capsules) once daily |
| Common Side Effects | Diarrhea, urinary tract infection, vaginal infection |
| Serious Side Effects | None well established. Consult with your healthcare provider immediately if you experience any new or worsening symptoms. |
| Drug Interactions | Potential interactions with drugs that affect liver enzymes (e.g., CYP3A4 inducers or inhibitors). Consult a healthcare professional or pharmacist for a complete list. |
| Important Notes | Vyndaqel is specifically for ATTR-CM. Liver function should be monitored periodically. |
| Storage | Store at room temperature, away from moisture and heat. |
| Missed Dose | Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose. |
| Alternatives | Onpattro (patisiran), Tegsedi (inotersen) |
Vyndaqel Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Onpattro (patisiran) | RNA interference; reduces the production of transthyretin (TTR) | Administered intravenously. For hereditary transthyretin-mediated amyloidosis (hATTR). |
| Tegsedi (inotersen) | Antisense oligonucleotide; reduces the production of transthyretin (TTR) | Administered subcutaneously. For hereditary transthyretin-mediated amyloidosis (hATTR). |
| Diflunisal | NSAID that stabilizes TTR | Off-label use for TTR stabilization. Consult a physician before considering this option. |
Vyndaqel Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Diarrhea | None well established. |
| Urinary Tract Infection | Consult with your healthcare provider immediately if you experience any new or worsening symptoms. |
Vyndaqel Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 80 mg daily (four 20mg capsules) | 80 mg daily (four 20mg capsules) | Take orally, once daily. Can be taken with or without food. |
